scholarly journals Osteopontin expression in papillary thyroid carcinoma and its relationship with theBRAFmutation and tumor characteristics

2013 ◽  
Vol 84 (1) ◽  
pp. 9 ◽  
Author(s):  
Kyung Ho Kang
2018 ◽  
Vol 37 (4) ◽  
pp. 323-329 ◽  
Author(s):  
Vivian Youngjean Park ◽  
Eun-Kyung Kim ◽  
Jin Young Kwak ◽  
Jung Hyun Yoon ◽  
Hee Jung Moon

1999 ◽  
Vol 32 (3) ◽  
pp. 281-285 ◽  
Author(s):  
Huagang Zhu ◽  
Yoichiro Kato ◽  
Reiko Tanaka ◽  
Takao Obara ◽  
Kanji Sato ◽  
...  

Author(s):  
Jordan Reilly ◽  
Erfan Faridmoayer ◽  
Morta Lapkus ◽  
Jacquelyn Pastewski ◽  
Fionna Sun ◽  
...  

2020 ◽  
Author(s):  
Junhao Ma ◽  
Zhuochao Mao ◽  
Yimin Lu ◽  
Haohao Wang ◽  
Jun Yang ◽  
...  

Abstract Background :Coexistence of primary hyperparathyroidism (PHPT) and PTC is common and may be associative with more aggressive papillary thyroid carcinoma (PTC) for higher rates of extrathyroidal extension and multicentricity. However, it remains unclear whether secondary hyperparathyroidism (SHPT) accounts for more invasive PTC in terms of morbidity, tumor pathological characteristics and prognosis . The aim of this study was to evaluate the rate and tumor characteristics of PTC in patients operated for secondary hyperparathyroidism (SHPT).Methods:A total of 531 patients with PTC who underwent surgery were evaluated retrospectively from January 2013 to December 2018 in the first affiliated hospital of the Zhejiang University. Patient demographics, operative and postoperative outcomes were recorded and analyzed. Among them, 34 patients of co-occurrence of secondary hyperparathyroidism and papillary thyroid carcinoma (PTC+SHPT) were enrolled. Control subjects were derived through 1:4 matching for age, sex and gender pathological subtype. 34 patients of co-occurrence of secondary hyperparathyroidism and papillary thyroid carcinoma (PTC+SHPT) were selected as control group after matching 1:4 for age, gender and pathological subtype.Results:There were 34 patienst coexisting with PTC+SHPT among the 531 surgery patients of SHPT(6.4%). Mean tumor diameter of group PTC+SHPT was smaller than that in group PTC (5.57mm vs 9.00mm, p=0.000). The proportion of papillary thyroid microcarcinoma(PTMC,means PTC with a diameter smaller than 10 mm) in group PTC+SHPT were significantly higher than that in group PTC [29 (85.29%) vs 86 (63.24%), P=0.014]. There were no statistically significant difference among the tumor multicentricity [15 (44.12%) vs 39 (28.68%), P=0.066], tumor bilaterally [9(26.47%) vs29(21.32%), P=0.499],tumor extrathyroidal extension [2(5.88%) vs19 (13.97%), P=0.255] and lymph node metastasises rate [12 (35.29%) vs 49 (36.03%), P=1.000]. We found differences between group PTC+SHPT and group PTC patients with respect to contralateral thyroidectomy [10 (29.41%) vs 70(51.47%), P=0.023] and lymph node dissection [22 (64.71%) vs 125(91.91%), P=0.000].There was no significant difference between group PTC+SHPT and group PTC in prognostic staging [33 (97.06%) vs 122 (89.71%), P=0.309] and recurrence [mean follow-up time 36 months vs 39 months, P=0.33].Conclusions: The prevalence of PTC is higher in patients with SHPT than in the general population. Compared with PTC in the general population, most of PTC with SHPT are occult thyroid carcinoma and present no significant difference in tumor multicentricity, tumor bilaterally,tumor extrathyroidal extension, lymph node metastasises and prognostic staging. It’s necessary for surgeons to make more adequate preoperative prediction and do more careful examination during the surgery in case of missing the coexistence of PTC in SHPT patients.


Head & Neck ◽  
2011 ◽  
Vol 33 (12) ◽  
pp. 1719-1726 ◽  
Author(s):  
Sang Soo Kim ◽  
Byung-Joo Lee ◽  
Jin-Choon Lee ◽  
Seong-Jang Kim ◽  
Soo Hyung Lee ◽  
...  

2001 ◽  
Vol 34 (3) ◽  
pp. 193-199 ◽  
Author(s):  
Yoichiro Kato ◽  
Huagang Zhu ◽  
Reiko Tanaka ◽  
Takao Obara ◽  
Kanji Sato ◽  
...  

Swiss Surgery ◽  
2003 ◽  
Vol 9 (2) ◽  
pp. 63-68
Author(s):  
Schweizer ◽  
Seifert ◽  
Gemsenjäger

Fragestellung: Die Bedeutung von Lymphknotenbefall bei papillärem Schilddrüsenkarzinom und die optimale Lymphknotenchirurgie werden kontrovers beurteilt. Methodik: Retrospektive Langzeitstudie eines Operateurs (n = 159), prospektive Dokumentation, Nachkontrolle 1-27 (x = 8) Jahre, Untersuchung mit Bezug auf Lymphknotenbefall. Resultate: Staging. Bei 42 Patienten wurde wegen makroskopischem Lymphknotenbefall (cN1) eine therapeutische Lymphadenektomie durchgeführt, mit pN1 Status bei 41 (98%) Patienten. Unter 117 Patienten ohne Anhalt für Lymphknotenbefall (cN0) fand sich okkulter Befall bei 5/29 (17%) Patienten mit elektiver (prophylaktischer) Lymphadenektomie, und bei 2/88 (2.3%) Patienten ohne Lymphadenektomie (metachroner Befall) (p < 0.005). Lymphknotenrezidive traten (1-5 Jahre nach kurativer Primärtherapie) bei 5/42 (12%) pN1 und bei 3/114 (2.6%) cN0, pN0 Tumoren auf (p = 0009). Das 20-Jahres-Überleben war bei TNM I + II (low risk) Patienten 100%, d.h. unabhängig vom N Status; pN1 vs. pN0, cN0 beeinflusste das Überleben ungünstig bei high risk (>= 45-jährige) Patienten (50% vs. 86%; p = 0.03). Diskussion: Der makroskopische intraoperative Lymphknotenbefund (cN) hat Bedeutung: - Befall ist meistens richtig positiv (pN1) und erfordert eine ausreichend radikale, d.h. systematische, kompartiment-orientierte Lymphadenektomie (Mikrodissektion) zur Verhütung von - kurablem oder gefährlichem - Rezidiv. - Okkulter Befall bei unauffälligen Lymphknoten führt selten zum klinischen Rezidiv und beeinflusst das Überleben nicht. Wir empfehlen eine weniger radikale (sampling), nur zentrale prophylaktische Lymphadenektomie, ohne Risiko von chirurgischer Morbidität. Ein empfindlicherer Nachweis von okkultem Befund (Immunhistochemie, Schnellschnitt von sampling Gewebe oder sentinel nodes) erscheint nicht rational. Bei pN0, cN0 Befund kommen Verzicht auf 131I Prophylaxe und eine weniger intensive Nachsorge in Frage.


Sign in / Sign up

Export Citation Format

Share Document